Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
100 hedge funds and large institutions have $925M invested in Aimmune Therapeutics in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 8 closing their positions.
819% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $1.24M
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
22% more capital invested
Capital invested by funds: $757M → $925M (+$168M)
4% more funds holding
Funds holding: 96 → 100 (+4)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$11.7M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$6.27M |
| 3 |
BlackRock
New York
|
+$3.41M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.15M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.18M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$3.71M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.29M |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$3.23M |
| 5 |
AG
Artal Group
Luxembourg
|
-$2.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Invesco
Atlanta,
Georgia
| – | -$1.16M | -56,197 | Closed |
|
|
HP
102
Hikari Power
Tokyo,
Japan
| – | -$617K | -30,000 | Closed |
|
|
GCP
103
GSA Capital Partners
London,
United Kingdom
| – | -$442K | -21,500 | Closed |
|
|
SSA
104
Schonfeld Strategic Advisors
New York
| – | -$407K | -19,840 | Closed |
|
105
Creative Planning
Overland Park,
Kansas
| – | -$56K | -2,720 | Closed |
|
106
Simplex Trading
Chicago,
Illinois
| – | -$6.79K | -315 | Closed |
|
AIMT Hedge Fund Activity: Q3 2017 in Review
100 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2017, worth a combined $925M — up 22% from $757M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AIMT positions and 8 closed out — a net gain of 4 holders — while 38 added to existing stakes and 28 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $11.7M. The largest seller was Adage Capital Partners, cutting an estimated $6.18M.
- 100 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2017, up from 96 in Q2 2017.
- Funds reported $925M of Aimmune Therapeutics stock for Q3 2017, up 22% quarter-over-quarter.
- 12 funds opened new Aimmune Therapeutics positions in Q3 2017 and 8 closed out, a net change of +4 holders.
- The largest Aimmune Therapeutics buyer in Q3 2017 was Citadel Advisors, an estimated $11.7M added.
- The largest Aimmune Therapeutics seller in Q3 2017 was Adage Capital Partners, an estimated $6.18M sold.
Based on aggregated 13F filings for Q3 2017.